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Summary We studied 83 lung cancer patients and 129 controls for the EcoRI polymorphism of the L-myc
gene. No association was found between the L-myc RFLP and increased risk of metastasis, either to lymph
nodes or metastasis to other organs. There was no difference in survival time between the three different
genotypes. The S-allele of the L-myc RFLP has been correlated to increased metastasis in lung cancer. We
found no tendency towards a highe, frequency of this allele in the cohort of patients with positive family
history compared to the patients with no known first degree relatives with cancer. A higher frequency of the
S-allele in the adenocarcinomas compared to other histological groups was found, although this difference was
not statistically significant. No difference in the gene frequency of the L-myc RFLP was found between the
lung cancer patients and the normal controls. These results are in contrast with a previous report. Possible
explanations for the discrepencies are discussed.
The myc family oncogenes are known to be involved in a
variety of different cancers (Alt et al., 1986). It is not known,
however, where in the carcinogenesis the myc genes are
involved, but some results indicate that amplification and
rearrangements of myc genes occur during tumour progres-
sion and not in the initial steps (Bishop, 1987). The myc
genes restrain differentiation and are thought to be involved
in proliferation.
The L-myc gene was initially identified by Nau et al. (1985)
as a gene with structural similarity to c-myc and N-myc from
a human SCLC cell line and was further characterised and
sequenced by Kaye et al. (1988). The gene was found to
encode multiple DNA-binding phosphoproteins made from
alternatively processed mRNAs (DeGreve et al., 1988).
The expression of the L-myc gene is restricted to fetal
brain, kidney and lung tissue and adult lung tissue, while the
expression of the c-myc is more generalised (Zimmerman et
al., 1986). The expression of L-myc in both neonatal and
adult lung is intriguing because the endocrine cells that give
rise to small cell lung cancer (SCLC) are abundant in fetal
lung and persist in reduced number in the adult lung.
The regulation of expression of the myc genes is complex
(Krystal et al., 1988). The L-myc gene seems to be regulated
differently from the other myc genes (Saksela, 1987; DeGreve
et al., 1988).
In the search for genetic markers for cancer susceptibility
as well as for diagnostic prognosis, restriction fragment
length polymorphisms (RFLPs) of known oncogenes like
L-myc, have been particularly considered. The influence of
polymorphic variants of the human c-Haras gene on predis-
position to lung cancer has also been investigated (Heighway
et al., 1986; Rydberg et al., 1990). A site polymorphism
within the L-myc locus using the EcoRI enzyme has been
described (Nau et al., 1985). Three different genotypes (LL,
LS, SS) consisting of two different alleles; L (large, 10kb) and
S (small, 6kb) are seen. Kawashima et al. (1988) reported a
correlation between this polymorphism of L-myc and the
prognosis of lung cancer patients. Patients homozygote for
the L-band had fewer lymph node metastatic lesions and less
metastasis to other organs. Kawashima et al. (1988) proposed
that this L-myc polymorphism could be a useful marker for
predicting the metastatic potential of human lung cancer.
In a study of colorectal cancer Kawashima et al. (1987)
found a correlation between increased metastasis and the
S-allele of the L-myc EcoRI RFLP. A similar study by Ikeda
et al. (1988) did not confirm these findings. Nor did they
observe any specific allele association with colon cancer, as
reported by Kawashima et al. (1987). On the other hand,
Kakehi and Yoshida (1989) found a significant lower
incidence of metastasis among patients with the LL-genotype
compared to patients with the LS or SS genotype in a
Japanese study of 50 renal cancers.
We have analysed a group of Norwegian primary lung
cancer patients and controls for the L-myc EcoRI RFLP in
order to investigate whether a correlation to the L-myc S-
allele and increased risk for metastasis could be found in our
population.
Materials and methods
Patients and controls
Blood samples from 83 consecutive lung cancer patients,
admitted to The Norwegian Radium Hospital were collected
between May 1987 and February 1988. The study included
all major histological groups of lung cancer. Data such as
age, sex and type of pathological diagnosis are included in
Table II. The patients were 73 men and 10 women, 43-85
years of age.
Information about cancers in the family, smoking habits
and possible occupational or other exposure to known lung
carcinogens were obtained from the hospital files. In addition
all patients available (n = 30) were interviewed about family
history.
Tumour size and metastasis to lymph nodes and other
organs were evaluated by computer tomography. Almost all
the lung cancer cases were TNM classified according to the
UICC guidelines (version 1989). This was done by a trained
clinician. The samples were collected before any
chemotherapeutic or radiation therapy treatment had been
started. The 129 controls were students and laboratory staff.
Both the patients and the controls were Norwegian
caucasians. All samples were stored at -40°C until isolation
of DNA.
DNA isolation and Southern blot analysis ofthe L-myc gene
DNA was isolated from the leukocytes in 20 ml EDTA blood
by a method adopted from Kunkel et al. (1977) with the
following modifications. Twenty ml EDTA blood was diluted
with 30 ml cold buffer (0.32 M sucrose, 5 mM MgC12, 1%
Triton X-100 and 0.01 M Tris-HCI, pH 7.6 at 25C),
vortexed and centrifuged for 15min at 2,500g. The pellet
was gently ground with a glass rod, resuspended in 50 ml of
the same buffer, and centrifuged (3,500 g, 15 min).
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The leukocyte pellet was suspended in 2 ml of 75 mM
NaCI, 24mM NaEDTA, pH 8.0 and frozen for 20 min at
- 70C before addition of 7 ml of the same salt solution, 1 ml
of 5% SDS and 50 mg ml' proteinase K. The mixture was
incubated with gentle rocking overnight at 37°C. After one
phenol and two chloroform extractions DNA was
precipitated with cold ethanol, resuspended in TE buffer
(10 mM Tris HC1, pH 7.6, 1 mM NaEDTA) and stored at
4°C. The yield of DNA ranged between 30-50 fig ml ' whole
blood. Eight lag DNA from each sample was digested with
EcoRI and electrophoresed in a 1% agarose gel, denaturated
and transferred in an alkaline solution (0.6 M NaCl, 0.4 M
NaOH) to a Zeta probe membrane (BioRad) by the method
essentially described by Southern (1975).
The 1.8 kilobase human L-myc fragment from plasmid
pJB327 was isolated from gel after digestion with SmaI and
EcoRI and labelled with 32p using Amersham multiprime
labelling kit (Feinberg & Vogelstein, 1983). The recombinant
plasmid pJB327 containing the Smal-EcoRI fragment of the
human L-myc was kindly provided by J.D. Minna. Hyb-
ridisation was performed with the labelled probe in 0.5 M
phosphate buffer pH 7.2 with 7% SDS at 65°C followed by
several stringency washes in 0.04 M Na2PO4 and 1% SDS.
Autoradiograms were developed at - 70°C using Amersham
Hyperfilm-MP and Kodak Super-Rapid intensifying screens
for 1-5 days.
Table I L-myc RFLP pattern in the lung cancer patients and the
control group
Total LL LS SS
LC-patients 83 21 37 25
Controls 129 35 59 35 P= 0.88
Table II Data on patients with lung cancer and the distribution ofthe
L-myc genotypes
DNA pattern ofL-myc
no. ofcases
Total LL LS SS
Total number 83 21 37 25
Age (years)
<49 7 2 2 3~-
50-69 49 12 22 15
70 27 7 13 7
Sex
Male 73 20 32 21
Female 10 1 5 4
Diagnosis
Squamous cell carcinoma 29 8 12 9
Small cell lung cancer 23 7 9 7
Adenocarcinoma 18 3 8 7
Large cell cancer 6 2 4 0
Other 7 1 4 2
Statistics
The groups were compared using x2 test and Mann-Whitney
U test.
Results
The EcoRI digest of human genomic DNA contains two
L-myc related fragments of 10 kb (large = L) and 6 kb (small
= S) which have been shown by Nau et al. (1985) to be due
to a polymorphic EcoRI site. A typical autoradiogram with
the three genotypes is shown in Figure 1.
Table I shows the distribution of the three genotypes in the
lung cancer patients compared to the control group. There
are no significant differences in frequency of the L and S
alleles in the two groups. The frequencies of the L and S
alleles are 0.5 for both alleles in the control group, 0.48 for
the L-allele and 0.52 for the S-allele for the lung cancer
patients. This is similar to the gene frequencies found by Nau
et al. (1985) when their results from tumour material and
controls were pooled (166 alleles) (L = 0.51, S = 0.49).
The distribution of the different genotypes among the
different age and sex groups, and the histological groups is
shown in Table HI. The three different genotypes are
represented in all the major histological groups (adenocar-
cinoma, squamous cell carcinoma and large cell and small
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Figure 1 RFLP pattern of the three L-myc genotypes LS (1), SS
(2) and LL (3).
cell lung cancer) except large cell lung cancer where no SS
genotype was found. The latter is probably due to the overall
small number of this histological group. The histological
group 'others' includes poor differentiated carcinoma, car-
cinoid, and non-small cell lung cancer. The three genotypes
in the adenocarcinoma seem to be distributed differently
when compared to the other histological groups. The over-
representation in the LS and SS genotype in the adenocar-
cinomas is, however, not statistically significant when com-
pared to the other histological groups (P = 0.53) or to the
controls (P = 0.49).
The family histories of cancer were analysed in 42 of the
patients. There was no tendency towards an increased fre-
quency of the S-allele in the cohort with positive family
history compared to the cohort with no first degree relatives
with cancer (Table III).
There were only four non-smokers among the lung cancer
patients. One was of the LL, two of LS and one of the SS
genotype.
The results of the TNM classification and the distribution
of the different genotypes are listed in Table IV. The TNM
classification was mostly done retrospectively by means of
the patients' files. Thirteen of the cases could not be classified
with respect to tumour size and extension to adjacent struc-
tures. Most of the tumours were advanced and classified to
T3 or T4. Ten cases were classified to less advanced tumours
Tl or T2.
Only 11 patients had no evidence for metastasis to lymph
nodes, 23 could not be classified (Nx) and the rest (48) were
classified as positive for lymph metastasis NI, N2, or N3. 53
persons did not have any sign of metastasis to other organs
while 23 did. Seven could not be classified according to
metastasis.
There was no correlation between the SS genotype and
increased metastasis to distal organs or to lymph nodes as
found by Kawashima et al. (1988). On the contrary, there
was a striking similarity of the distribution of the three
genotypes among different stages.
Table III The distribution ofthe L-myc genotypes in the lung cancer
patients with one or more first degree relatives with cancer (+ )
compared with lungcancerpatients with no known first degree relatives
with cancer (-)
Family history Total LL LS SS
+ 20 5 7 8
- 22 6 9 7 P= 0.86L-myc DNA POLYMORPHISM AND METASTASIS 811
Table IV TNM-classification of the lung cancers patients and the
distribution of the different L-myc genotypes
Genotype Total Tumour size classification
Ti T2 T3 T4 TX
LL 21 0 1 9 9 2
LS 37 0 1 15 13 8
SS 25 1 7 9 9 3
Node classification
NO N1 N2 N3 NX
LL 21 4 1 12 1 3
LS 37 5 4 13 1 14
SS 25 3 2 14 0 6
Metastatic classification
MO Ml MX
LL 21 15 5 1
LS 37 23 9 5
SS 25 15 9 1
Figure 2 illustrates the time of survival of the patients with
the three different genotypes after pronounced symptoms of
lung cancer. The diagnosis of lung cancer was confirmed
approximately month later. After I year, half of the
population was dead and after 3 years less than 10% were
still living. This is in accordance with observations at the
Norwegian Cancer Registry (Kvale & Johansen, 1982) for the
whole population of Norwegian lung cancer patients. No
differences in survival between the three different genotypes
were seen (LL versus SS P = 0.43, LL versus LS P = 0.99, LS
versus SS P=0.21).
Discussion
This study was conducted to investigate, whether we could
confirm the correlation between the L-myc genotype SS and
increased metastasis to lymph nodes and distal organs in
lungs cancer patients previously reported by Kawashima et
al. (1988). No such correlation could be found in our popula-
tion of 83 lung cancer patients, nor was there any difference
in time of survival between the three different genotypes LL,
LS and SS.
There are three possible explanations for this discrepancy:
random variation, stratification and/or linkage disequilib-
rium. Firstly, the different results could be due to random
variation prone to occur when the populations studied are
relatively small. We did not find any differences in allele
frequencies between the control and lung cancer population
and both were similar to the frequencies published by Nau et
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Figure 2 Survival time (in months) of lung cancer patients in the
three different genotypes of the L-myc gene, LL (n = 17), LS
(n = 35) and SS (n = 23). The time of survival is given from onset
of illness with pronounced symptoms to death ( %
survival LL; * % survival LS; % survival
SS).
al. (1985). In the Japanese lung cancer population there was
a higher frequency of the S-allele (L = 0.37, S = 0.67) com-
pared to control (L = 0.43, S = 0.57, n = 20). The increased
frequency of the S-allele in the lung cancer patients was due
to the many SS-genotypes in the adenocarcinomas. A similar
trend could be seen among our adenocarcinomas (LL = 3,
LS = 8, SS = 7) when compared to the other histological
groups (LL = 18, LS = 29, SS = 18).
It has been proposed that adenocarcinoma is less cor-
related to smoking than other histological groups of lung
cancer (Fraumeni & Blot, 1982; IARC, 1986). An
epidemiological study (Anton-Culver, 1988) also indicates
that it could be due to differences in the aetiology of
adenocarcinoma and other histological types, since the
adenocarcinoma are diagnosed at a younger age than other
types of lung cancer. Adenocarcinoma is also the most com-
mon type among women regardless of smoking habits.
Squamous cell carcinoma is the most common histological
type of lung cancer among men. An increased risk of
adenocarcinoma linked to the SS allele could be consistent
with our data. This has to be confirmed in a larger series of
patients.
Secondly, the different results could be explained by
stratification in the ascertainment of the patients in the
Japanese, in the Norwegian or in both studies. There are
some differences between the two lung cancer populations.
All the Japanese lung cancer patients except for the small cell
lung cancers underwent surgery. Tumour size and metastasis
to local lymph nodes could then easily be determined at the
time of operation. All our patients had advanced and
inoperable disease and information about tumour size and
lesion to lymph nodes was more difficult to obtain. In a
cohort of lung cancer patients with advanced illness one
could fail to detect the difference in metastasis if this
polymorphism is linked to the speed of the metastasis pro-
cess. On the other hand, if the presence of the S-allele is
correlated to the metastatic process, a higher frequency of the
S-allele would be expected in a population with advanced
cancer compared to controls. This was not seen in our
population.
A third explanation for the difference between
Kawashimas and our results may be that L-myc is not
important, but is linked to a gene which is involved in the
metastatic process. Linkage disequilibrium may differ in
genetic distant populations. Furthermore, the polymorphic
EcoRI site is in the second intron outside the area trans-
cribed and is not likely to be directly involved in the regula-
tion of the gene expression or have any consequence for the
amino acid sequence in the protein. Thus, Kawashima et al.
(1988) may have described a node or metastasis-disposing
haplotype in their population which we did not find.
Kawashima et al. (1988) refer to unpublished results which
show no correlation between increased metastasis and the
S-allele when the typing was made one year or more after the
initial diagnosis. Their explanation for this discrepancy is
that the S-allele is associated with the speed and extent of
metastasis and not to the incidence of metastasis. The
similarity in the survival rate in the three genotypes in our
patients support the hypothesis that there is no correlation
between SS and LS genotype and metastasis. If there were
any differences, either in the incidence or speed of metastasis
between these three genotypes, a different time of survival
would be expected. No such difference was found.
The results of our study therefore seem to demonstrate
that RFLP typing of the L-myc has limited or no value as a
prognostic marker in lung cancer, particularly for the non-
adenocarcinomas in our population.
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